Evidence map›Paper›PMID 39379026›Full record

ArticleAmerican journal of perinatology2025

Clinical Analysis of Inhaled Nitric Oxide Therapy in Preterm Infants at Different Gestational Ages: A National Retrospective Multicenter Study.

Guo-Bao Liang, Lian Wang, Sheng-Qian Huang, Bao-Ying Feng, Mu-Lin Yao, Xu-Fang Fan, Meng-Jiao Wang, Lu Zhu, Jing Zhang, Zhi Zheng and 11 more

Abstract readMulticenter Study
In one paragraph

Article in American journal of perinatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Guo-Bao LiangDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Lian WangDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Sheng-Qian HuangDepartment of Neonatology, Guiyang Maternal and Child Health Care Hospital, Guiyang Children's Hospital, Guiyang, Guizhou, China.
Bao-Ying FengDepartment of Neonatology, Maternal and Child Health Hospital of the Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Mu-Lin YaoDepartment of Neonatology, Children's Hospital of Hebei Province, Shijiazhuang, Hebei, China.
Xu-Fang FanDepartment of Neonatology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Meng-Jiao WangDepartment of Neonatology, Northwest Women's and Children's Hospital, Xi'an, Shanxi, China.
Lu ZhuDepartment of Neonatology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Jing ZhangDepartment of Neonatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Zhi ZhengDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Yao ZhuDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Wei ShenDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Wen-Li DuanDepartment of Neonatology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jian MaoDepartment of Neonatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Fan WuDepartment of Neonatology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhan-Kui LiDepartment of Neonatology, Northwest Women's and Children's Hospital, Xi'an, Shanxi, China.
Fa-Lin XuDepartment of Neonatology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0000-0002-7934-0424
Li MaDepartment of Neonatology, Children's Hospital of Hebei Province, Shijiazhuang, Hebei, China.
Qiu-Fen WeiDepartment of Neonatology, Maternal and Child Health Hospital of the Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Ling LiuDepartment of Neonatology, Guiyang Maternal and Child Health Care Hospital, Guiyang Children's Hospital, Guiyang, Guizhou, China.
Xin-Zhu LinDepartment of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate clinical features of inhaled nitric oxide (iNO) in preterm infants with a gestational age (GA) < 34 weeks in China.The clinical data of 434 preterm infants with GA < 34 weeks, treated with iNO in the neonatology departments of eight Class A tertiary hospitals in China over a 10-year period from January 2013 to December 2022, were included in this retrospective multicenter investigation. The infants were divided into three groups based on GA: 24 to 27 weeks (extremely preterm infants), 28 to 31 weeks (very preterm infants), and 32 to 33 weeks (moderate preterm infants). The use of iNO, perinatal data, incidence and mortality of indication for iNO treatment, therapeutic effects of iNO, incidence of short-term complications for iNO treatment, and mortality were compared among these three groups.Over the past 10 years, the proportion of iNO use was highest in extremely preterm infants each year. The lower the GA, the higher the iNO use rate: 4.20% for GA 24 to 27 weeks, 1.54% for GA 28 to 31 weeks, and 0.85% for GA 32 to 33 weeks. There was no significant difference in the therapeutic effect of iNO among the three groups. The incidence of neonatal pulmonary hemorrhage, neonatal shock, late-onset diseases, retinopathy of prematurity requiring intervention, intracranial hemorrhage (grade 3 or 4), periventricular leukomalacia, neonatal necrotizing enterocolitis (≥stage II), and moderate to severe bronchopulmonary dysplasia was highest in extremely preterm infants and increased with decreasing GA. Mortality was negatively correlated with GA and birth weight. The highest rate of iNO treatment in 24 to 27 weeks' preterm infants was due to hypoxic respiratory failure (HRF), whereas the highest rate of iNO treatment in 32 to 33 weeks' preterm infants was due to documented persistent pulmonary hypertension of the newborn (PPHN). The rates of iNO treatment due to HRF and documented PPHN were 54.3 and 60.6%, respectively, in extremely preterm infants, significantly higher than in very preterm and moderate preterm infants (all

Indexed as

Bronchodilator AgentsInfant, Premature, DiseasesNitric OxideRespiratory Distress Syndrome, NewbornAdministration, InhalationBronchopulmonary DysplasiaChinaEnterocolitis, NecrotizingFemaleGestational AgeHumansInfant, Extremely PrematureInfant, NewbornInfant, PrematureMaleRetrospective StudiesBronchodilator AgentsNitric Oxide

Identifiers

PMID39379026
PMCPMC12020719

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.